Description:Avapritinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancers, particularly those associated with mutations in the KIT gene, such as gastrointestinal stromal tumors (GISTs). It selectively inhibits the activity of mutant forms of the KIT protein, which plays a crucial role in cell signaling pathways that regulate cell growth and survival. Avapritinib is characterized by its high specificity for the mutant forms of the target, which helps minimize off-target effects and enhances its therapeutic efficacy. The compound is administered orally and has a favorable pharmacokinetic profile, allowing for effective systemic exposure. Its development was driven by the need for targeted therapies in oncology, and it has been evaluated in clinical trials for its safety and efficacy. As with many targeted therapies, potential side effects may include hematologic abnormalities, gastrointestinal disturbances, and fatigue, necessitating careful monitoring during treatment. Overall, Avapritinib represents a significant advancement in personalized cancer therapy.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
